Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
June 02, 2024 10:55 ET
|
Seer, Inc.
REDWOOD CITY, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced today that...
Nanobiotix annonce de nouvelles données montrant un contrôle de la maladie et une réponse tumorale chez des patients traités avec NBTXR3 activé par radiothérapie suivi d’un anti-PD-1, comme traitement de deuxième intention ou plus, dans le cancer de la tête et du cou récurrent ou métastatique, naïf ou résistant aux anti-PD-1
June 02, 2024 10:00 ET
|
Nanobiotix S.A.
Traitement faisable et bien toléré chez 68 patients fortement prétraités atteints de CETEC-R/M (population en intention de traiter, ITT) qui ont reçu NBTXR3 activé par radiothérapie suivi d’un...
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
June 02, 2024 10:00 ET
|
Nanobiotix S.A.
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a...
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
June 02, 2024 10:00 ET
|
ALX Oncology
Evorpacept in combination with PADCEV®, an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with...
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
June 02, 2024 09:01 ET
|
Celldex Therapeutics, Inc.
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups -- Sustained activity with rapid onset within 2 weeks -- Data...
NVIDIA Enables Real-Time Healthcare, Industrial and Scientific AI Applications at the Edge With Enterprise Software Support for NVIDIA IGX With Holoscan
June 02, 2024 08:56 ET
|
NVIDIA
TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- To address the increasing need for real-time AI computing at the industrial edge, NVIDIA today announced the general software...
NVIDIA Robotics Adopted by Industry Leaders for Development of Tens of Millions of AI-Powered Autonomous Machines
June 02, 2024 08:52 ET
|
NVIDIA
TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced that the world’s leaders in robot development are adopting the NVIDIA Isaac™ robotics platform for the research,...
Robotic Factories Supercharge Industrial Digitalization as Electronic Makers Adopt NVIDIA AI and Omniverse
June 02, 2024 08:44 ET
|
NVIDIA
TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced that major Taiwanese electronics makers are using the company’s technology to transform their factories into more...
NVIDIA Brings AI Assistants to Life With GeForce RTX AI PCs
June 02, 2024 08:41 ET
|
NVIDIA
TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced new NVIDIA RTX™ technology to power AI assistants and digital humans running on new GeForce RTX™ AI laptops. ...
Computer Industry Joins NVIDIA to Build AI Factories and Data Centers for the Next Industrial Revolution
June 02, 2024 08:35 ET
|
NVIDIA
Top Computer Manufacturers Unveil Array of Blackwell-Powered Systems Featuring Grace CPUs, NVIDIA Networking and InfrastructureBroad Portfolios Encompass Cloud, On-Premises, Embedded and Edge AI...